Influence of estrogen administration on growth hormone response to GHRH and L-Dopa in patients with Turner's syndrome.
The modulating effect of estrogen on GH secretion was studied in 22 patients with Turner's syndrome. Estrogen administration (0.5 microgram/kg ethinylestradiol) for a period of 4 weeks resulted in a significant increase in basal GH concentrations (2.6 vs 4.8 micrograms/l, P less than 0.01). The L-Dopa-stimulated GH concentrations were also significantly increased (P less than 0.01), whereas no effect of estrogen substitution on GH responses to GHRH (1-44) and Sm-C levels was seen. Our findings demonstrate a priming effect of estrogen on GH secretion in patients with Turner's syndrome. These patients generally lack the puberty-associated rise in GH secretion, which might be due to ovarian failure and the concomitant estrogen deficiency.
Schober
E
E
Department of Pediatrics, University of Vienna, Austria.
Frisch
H
H
Waldhauser
F
F
Bieglmayr
C
C
D000293:Adolescent; D001835:Body Weight / Q000187:drug effects; D004997:Ethinyl Estradiol / Q000008:administration & dosage*; D005260:Female; D013006:Growth Hormone / Q000097:blood / Q000378:metabolism*; D013007:Growth Hormone-Releasing Hormone / Q000494:pharmacology*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000097:blood; D007980:Levodopa / Q000494:pharmacology*; D010446:Peptide Fragments / Q000494:pharmacology*; D014424:Turner Syndrome / Q000097:blood / Q000503:physiopathology*
D010446:Peptide Fragments; C036893:somatotropin releasing factor 40; D004997:Ethinyl Estradiol; D007980:Levodopa; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone